What Glenmark Life Sciences does

Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, is a Mumbai-based developer and manufacturer of select high-value, non-commoditized Active Pharmaceutical Ingredients (APIs) focused on chronic therapeutic areas, including cardiovascular, diabetes (notably SGLT2 inhibitors such as empagliflozin, dapagliflozin, and canagliflozin), and respiratory treatments. The company was originally carved out of Glenmark Pharmaceuticals in 2019 and operates as a vertically integrated pharmaceutical ingredient platform, offering process development, analytical development and support, and commercial-scale API and intermediate manufacturing. Beyond core APIs, Alivus provides Contract Development and Manufacturing Organization (CDMO) services to pharmaceutical partners seeking end-to-end support. More recently, the company has expanded into finished dosage form generics, including FDA-approved Fluticasone Propionate Inhalation Aerosol (with 180-day competitive generic therapy exclusivity in the U.S. respiratory market) and Sodium Phosphates Injection USP targeting the institutional channel.

The company operates a direct B2B sales model supplying APIs and CDMO services to global pharmaceutical partners across North America, Europe, Japan, LATAM, India, and Rest of World markets. Revenue is generated through negotiated, quote-based contracts reflecting volume, regulatory complexity, and service scope; pricing is not publicly disclosed. Following Nirma Limited's March 2024 acquisition of a 75% stake for approximately $682 million, the entity was rebranded as Alivus Life Sciences in 2025 and operates as a private limited company under Nirma's ownership umbrella, with the remaining 25% held by legacy shareholders. Headcount is reported in the 1,001–5,000 range, consistent with mid-scale API manufacturing operations serving regulated markets.

Name

Glenmark Life Sciences

Legal name

Alivus Life Sciences Limited

Website

https://glenmarklifesciences.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Alivus Life Sciences (formerly Glenmark Life Sciences) is a Mumbai-based developer and manufacturer of non-commoditized Active Pharmaceutical Ingredients (APIs) and CDMO services for chronic therapeutic areas, serving global pharmaceutical partners across North America, Europe, Japan, LATAM, and India.

Ownership category

akta.pro rank

Product category

Active Pharmaceutical Ingredients

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Small-Molecule API Commercial Manufacturing (HLAGAHAB), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

Keywords

• Active pharmaceutical ingredients
• Contract development manufacturing
• Chronic disease APIs
• High-potency API manufacturing
• Pharmaceutical intermediates supply

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. API Sales: Development, manufacturing and supply of high-quality Active Pharmaceutical Ingredients (APIs) to pharmaceutical partners globally. Revenue generated through direct API sales to customers in regulated markets.
2. CDMO Services: Contract Development and Manufacturing services providing end-to-end support including process development, analytical development and API manufacturing for pharmaceutical partners.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Glenmark Life Sciences develops, manufactures, and markets Active Pharmaceutical Ingredients (APIs) in chronic therapeutic areas including cardiovascular, central nervous system, diabetes, and respiratory segments. The company provides end-to-end CDMO services spanning process research, analytical development, KSM/intermediate/API manufacturing, formulation development, and commercial supply to global pharmaceutical partners. Its products are manufactured at USFDA-, EDQM-, and PMDA-approved facilities and are supplied to customers across regulated and emerging markets.

Product overview

Alivus Life Sciences (formerly Glenmark Life Sciences Limited) operates as a developer and manufacturer of select high-value, non-commoditized Active Pharmaceutical Ingredients (APIs) in chronic therapeutic areas. The company provides end-to-end support including process development, analytical development, and API & intermediate manufacturing through its CDMO services. Its product portfolio includes APIs for cardiovascular, diabetes, and respiratory treatments, as well as finished dosage form generics such as Fluticasone Propionate Inhalation Aerosol and Sodium Phosphates Injection USP. The company serves global markets including North America, Europe, Japan, LATAM, India, and ROW.

Differentiator

Problem solved

Functional benefit

Products and services

• Active Pharmaceutical Ingredients (APIs) for chronic therapeutic areas A portfolio of non-potent and high-potency Active Pharmaceutical Ingredients in cardiovascular, central nervous system, diabetes, and respiratory therapeutic areas, manufactured at USFDA-, EDQM-, and PMDA-approved facilities and supplied to global pharmaceutical companies for use in finished formulations.
• Contract Development and Manufacturing Organization (CDMO) services End-to-end contract development and manufacturing services covering process research, analytical development, KSM/intermediate/API manufacturing, formulation development, and commercial supply for pharmaceutical partner companies.
• Key Starting Materials (KSM) and Pharmaceutical Intermediates Key starting materials and chemical intermediates manufactured internally as part of the company's backward-integration strategy to secure supply continuity for its own APIs and for supply to pharmaceutical customers.
• Formulation Development and Finished Dosage Supply Pharmaceutical formulation development and finished dosage form commercial supply provided as part of the company's end-to-end CDMO services for pharmaceutical partners.

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Sun Pharmaceutical Industries: India's largest pharma company with significant API operations as well as generic finished products. Comparable as a domestic-API-plus-generics peer though far larger and more diversified.
• Aurobindo Pharma: Vertically integrated Indian pharma with substantial API manufacturing plus a large finished generics business. Overlaps on API/CDMO capabilities but operates at greater scale and breadth than Glenmark/Alivus.
• Zydus Lifesciences (Cadila Healthcare): Indian pharma group with active API manufacturing operations and a finished generics portfolio. Relevant domestic peer on API + finished dosage business model overlap.
• WuXi AppTec / WuXi STA: Large global CRDMO offering active pharmaceutical ingredients and intermediates. Comparable CDMO service offerings, though far broader and larger in scope.
• Dr. Reddy's Laboratories: Indian multinational with API manufacturing (Dr. Reddy's APIs) and a global generics franchise. Comparable in API + finished dosage strategic profile; operates at larger scale and broader therapeutic scope.

Direct peers

• Piramal Pharma Solutions: India-headquartered CDMO providing integrated drug substance and drug product services globally. Comparable end-to-end CDMO offering and similar B2B pharma customer profile.
• Laurus Labs: Indian integrated manufacturer of APIs, intermediates, and CDMO services with a heavy focus on chronic therapeutic areas (including SGLT2 antidiabetics). Closely matches Glenmark/Alivus's API-plus-CDMO positioning and regulated-market customer base.
• Divis Laboratories: India-based, publicly-listed API manufacturer with strong custom synthesis and CDMO exposure across regulated markets. Closely comparable business model mix of generic APIs plus contract research services, with similar customer base among global pharma partners.
• Cambrex (now part of Permira): Specialty CDMO focused on small-molecule API development and manufacturing from clinical through commercial stages. Direct comparable in integrated small-molecule CDMO service model.
• Recipharm: European-headquartered CDMO offering API development and manufacturing services, including in chronic therapeutic areas. Comparable contract development and manufacturing business serving global pharma clients.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/glenmark-life-sciences

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Glenmark Life Sciences